Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2019 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference

CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that...
September 30, 2019 10:30 ET | Source: Agios Pharmaceuticals, Inc.

Data from Agios’ Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients

– TIBSOVO® Reduced the Risk of Disease Progression or Death by 63% (HR=0.37, p<0.001); Median PFS for Patients Randomized to TIBSOVO® was 2.7 months Compared to 1.4 Months with Placebo – –...
September 10, 2019 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO

CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that...
September 04, 2019 17:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces Publication of Data for Mitapivat from Core and Extension Phases of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency in the New England Journal of Medicine

– Maximum Hemoglobin Increases >1.0 g/dL Observed in 50% of Patients in Core Period, Among Whom the Mean Maximum Hemoglobin Increase was 3.4 g/dL – – Hemoglobin Responses Maintained in 19...
August 29, 2019 16:05 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at the Citi 14th Annual Biotech Conference on Thursday, September 5, 2019

CAMBRIDGE, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
August 01, 2019 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Business Highlights and Second Quarter 2019 Financial Results

Strong Topline Performance for IDH Inhibitors: TIBSOVO® Net Revenue Increased 50% from Q1 2019 to $13.7M; IDHIFA® Royalty Increased to $2.7M Achieved Important Expansion Opportunities for TIBSOVO®...
July 18, 2019 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of Second Quarter 2019 Financial Results on August 1, 2019

CAMBRIDGE, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
July 01, 2019 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces Orlando Oliveira Appointed as Senior Vice President and General Manager, International

CAMBRIDGE, Mass., July 01, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
June 10, 2019 13:12 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019

CAMBRIDGE, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
June 05, 2019 16:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces the Planned Retirement of Chief Scientific Officer, Scott Biller, Ph.D., Effective December 31, 2019

– Search Initiated for Company’s Next Chief Scientific Officer – – Dr. Biller to Remain a Strategic Advisor to Agios Through 2020 – CAMBRIDGE, Mass., June 05, 2019 (GLOBE NEWSWIRE) -- Agios...